Fox E, et al. Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS). ECTRIMS 2018, abstract 229.
Vroegtijdig kanker ontdekken in druppel bloed
nov 2020 | Borstkanker, Longoncologie, Neuro-oncologie